Federal Register #2026-21909

FDA notice concerning Bixlenvo and a Material Threat MCM Priority Review Voucher

The Department of Health and Human Services’ Food and Drug Administration (FDA) issued a regulatory notice about Bixlenvo tablets and a Material Threat Medical Countermeasure Priority Review Voucher. - Government agency: HHS, through the FDA; this is an agency announcement, not a procurement solicitation. - Product discussed: Bixlenvo (bictegravir and lenacapavir) tablets. No manufacturer or vendor is identified in the provided information. - The FDA states that Bixlenvo meets the criteria for redemption of a Material Threat MCM Priority Review Voucher. The notice also addresses FDA authority and reporting obligations related to these vouchers and products approved after voucher redemption. - No products or services are requested for purchase, and no part numbers, quantities, or procurement-specific requirements are provided.

Description

The FDA announces approval of Bixlenvo (bictegravir and lenacapavir) tablets, approved August 27, 2026, as a product redeeming a material threat medical countermeasure priority review voucher. FDA determined that the product meets the voucher redemption criteria. The notice describes FDA’s statutory authority and reporting requirement for issuance of these vouchers and approval of products that redeem them.

View original listing